INCY vs. CRL, MEDP, EXEL, NRC, ICLR, IQV, EXAS, PODD, DVA, and RDY
Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Charles River Laboratories International (CRL), Medpace (MEDP), Exelixis (EXEL), National Research (NRC), ICON Public (ICLR), IQVIA (IQV), Exact Sciences (EXAS), Insulet (PODD), DaVita (DVA), and Dr. Reddy's Laboratories (RDY).
Charles River Laboratories International (NYSE:CRL) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Charles River Laboratories International presently has a consensus price target of $253.23, indicating a potential upside of 10.57%. Incyte has a consensus price target of $75.50, indicating a potential upside of 46.09%. Given Charles River Laboratories International's higher possible upside, analysts plainly believe Incyte is more favorable than Charles River Laboratories International.
Incyte received 727 more outperform votes than Charles River Laboratories International when rated by MarketBeat users. Likewise, 73.63% of users gave Incyte an outperform vote while only 61.57% of users gave Charles River Laboratories International an outperform vote.
Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Incyte has a net margin of 16.17% compared to Incyte's net margin of 11.49%. Incyte's return on equity of 16.53% beat Charles River Laboratories International's return on equity.
98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 17.5% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Incyte had 17 more articles in the media than Charles River Laboratories International. MarketBeat recorded 26 mentions for Incyte and 9 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.39 beat Incyte's score of 0.27 indicating that Incyte is being referred to more favorably in the news media.
Incyte has lower revenue, but higher earnings than Charles River Laboratories International. Incyte is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
Summary
Incyte beats Charles River Laboratories International on 10 of the 17 factors compared between the two stocks.
Get Incyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
